Cargando…

Human immunodeficiency virus is a driven factor of human papilloma virus among women: evidence from a cross-sectional analysis in Yaoundé, Cameroon

BACKGROUND: Human papillomavirus (HPV) is the leading cause of cervical cancers, causing 270.000 deaths annually worldwide of which 85% occur in developing countries with an increasing risk associated to HIV infection. This study aimed at comparing HPV’s positivity and genotype distribution in women...

Descripción completa

Detalles Bibliográficos
Autores principales: Sosso, Samuel Martin, Tchouaket, Michel Carlos Tommo, Fokam, Joseph, Simo, Rachel Kamgaing, Torimiro, Judith, Tiga, Aline, Lobe, Elise Elong, Ambada, Georgia, Nange, Achille, Semengue, Ezechiel Ngoufack Jagni, Nka, Alex Durand, Tala, Valère, Chenwi, Collins, Abba, Aissatou, Ka’e, Aude Christelle, Yagai, Bouba, Colizzi, Vittorio, Ndjolo, Alexis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7236111/
https://www.ncbi.nlm.nih.gov/pubmed/32430034
http://dx.doi.org/10.1186/s12985-020-01340-y
_version_ 1783536094885707776
author Sosso, Samuel Martin
Tchouaket, Michel Carlos Tommo
Fokam, Joseph
Simo, Rachel Kamgaing
Torimiro, Judith
Tiga, Aline
Lobe, Elise Elong
Ambada, Georgia
Nange, Achille
Semengue, Ezechiel Ngoufack Jagni
Nka, Alex Durand
Tala, Valère
Chenwi, Collins
Abba, Aissatou
Ka’e, Aude Christelle
Yagai, Bouba
Colizzi, Vittorio
Ndjolo, Alexis
author_facet Sosso, Samuel Martin
Tchouaket, Michel Carlos Tommo
Fokam, Joseph
Simo, Rachel Kamgaing
Torimiro, Judith
Tiga, Aline
Lobe, Elise Elong
Ambada, Georgia
Nange, Achille
Semengue, Ezechiel Ngoufack Jagni
Nka, Alex Durand
Tala, Valère
Chenwi, Collins
Abba, Aissatou
Ka’e, Aude Christelle
Yagai, Bouba
Colizzi, Vittorio
Ndjolo, Alexis
author_sort Sosso, Samuel Martin
collection PubMed
description BACKGROUND: Human papillomavirus (HPV) is the leading cause of cervical cancers, causing 270.000 deaths annually worldwide of which 85% occur in developing countries with an increasing risk associated to HIV infection. This study aimed at comparing HPV’s positivity and genotype distribution in women according to their HIV status and determinants. METHODS: A comparative study was carried out in 2012 at the Chantal BIYA International Reference Centre (CIRCB) among 278 women enrolled consecutively at the General Hospital and the Gynaeco-Obstetric and Paediatric Hospital of the City of Yaoundé. HPV genotyping was performed by real-time PCR, HIV serological screening by serial algorithm, CD4 T cell phenotyping by flow cytometry and HIV viral load by Abbott m2000RT. Statistical analyses were performed using Microsoft Excel 2016 and Graph Pad version 6.0 software; with P < 0.05 considered statistically significant. RESULTS: Globally, mean age was 37 ± 3 years; median CD4-count for HIV+ was 414 cells/mm(3) [IQR: 264.75–588] and median viremia was 50 RNA copies/mL [IQR: < 40–8288]. Overall HPV rate was 38.49% (107/278); 58.88% for single women vs. others (28.97% married, 2.80% divorced, 9.34% for widows), OR: 2.164; p = 0.0319. Following HIV status, HPV rate was 43.48% (80/184) among HIV+ vs. 28.72% (27/94) among HIV- (OR: 1.937; p < 0.0142); HPV genotypes among HIV+ vs. HIV- were respectively distributed as follows: genotype 16 (3.75% vs. 0.00%, p = 0.57), genotype 18 (3.75% vs. 3.70%, p = 1.00), co-infection 16 and others (8.75% vs. 7.40%, p = 1.00), co-infection 18 and others (8.75% vs. 11.11%, p = 0.71), co-infection 16, 18 and others (2.50% vs. 0.00%, p = 1.00) and other genotypes (72.50% vs. 77.78%, p = 0.80). Among HIV+ participants, HPV rate following CD4 was 62.88% (61/97) for CD4 < 500 vs. 35.71% (20/56) for CD4 ≥ 500 (OR: 3.05; p = 0.0012) while HPV rate following HIV viremia was 42.71% (41/96) with < 1000 RNA copies/ml vs. 66.00% (33/50) with > 1000 RNA copies/ml (OR = 0.384; p = 0.009). CONCLUSION: In Yaoundé, HPV rate appear to be very high, with higher rates of genotypes other than 16 and 18. In the event of HIV infection, the risk of HPV positivity is two times higher, favoured essentially by immunodeficiency. Thus, HIV-infected women should be closely monitored to prevent the emergence of cervical cancer.
format Online
Article
Text
id pubmed-7236111
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-72361112020-05-27 Human immunodeficiency virus is a driven factor of human papilloma virus among women: evidence from a cross-sectional analysis in Yaoundé, Cameroon Sosso, Samuel Martin Tchouaket, Michel Carlos Tommo Fokam, Joseph Simo, Rachel Kamgaing Torimiro, Judith Tiga, Aline Lobe, Elise Elong Ambada, Georgia Nange, Achille Semengue, Ezechiel Ngoufack Jagni Nka, Alex Durand Tala, Valère Chenwi, Collins Abba, Aissatou Ka’e, Aude Christelle Yagai, Bouba Colizzi, Vittorio Ndjolo, Alexis Virol J Research BACKGROUND: Human papillomavirus (HPV) is the leading cause of cervical cancers, causing 270.000 deaths annually worldwide of which 85% occur in developing countries with an increasing risk associated to HIV infection. This study aimed at comparing HPV’s positivity and genotype distribution in women according to their HIV status and determinants. METHODS: A comparative study was carried out in 2012 at the Chantal BIYA International Reference Centre (CIRCB) among 278 women enrolled consecutively at the General Hospital and the Gynaeco-Obstetric and Paediatric Hospital of the City of Yaoundé. HPV genotyping was performed by real-time PCR, HIV serological screening by serial algorithm, CD4 T cell phenotyping by flow cytometry and HIV viral load by Abbott m2000RT. Statistical analyses were performed using Microsoft Excel 2016 and Graph Pad version 6.0 software; with P < 0.05 considered statistically significant. RESULTS: Globally, mean age was 37 ± 3 years; median CD4-count for HIV+ was 414 cells/mm(3) [IQR: 264.75–588] and median viremia was 50 RNA copies/mL [IQR: < 40–8288]. Overall HPV rate was 38.49% (107/278); 58.88% for single women vs. others (28.97% married, 2.80% divorced, 9.34% for widows), OR: 2.164; p = 0.0319. Following HIV status, HPV rate was 43.48% (80/184) among HIV+ vs. 28.72% (27/94) among HIV- (OR: 1.937; p < 0.0142); HPV genotypes among HIV+ vs. HIV- were respectively distributed as follows: genotype 16 (3.75% vs. 0.00%, p = 0.57), genotype 18 (3.75% vs. 3.70%, p = 1.00), co-infection 16 and others (8.75% vs. 7.40%, p = 1.00), co-infection 18 and others (8.75% vs. 11.11%, p = 0.71), co-infection 16, 18 and others (2.50% vs. 0.00%, p = 1.00) and other genotypes (72.50% vs. 77.78%, p = 0.80). Among HIV+ participants, HPV rate following CD4 was 62.88% (61/97) for CD4 < 500 vs. 35.71% (20/56) for CD4 ≥ 500 (OR: 3.05; p = 0.0012) while HPV rate following HIV viremia was 42.71% (41/96) with < 1000 RNA copies/ml vs. 66.00% (33/50) with > 1000 RNA copies/ml (OR = 0.384; p = 0.009). CONCLUSION: In Yaoundé, HPV rate appear to be very high, with higher rates of genotypes other than 16 and 18. In the event of HIV infection, the risk of HPV positivity is two times higher, favoured essentially by immunodeficiency. Thus, HIV-infected women should be closely monitored to prevent the emergence of cervical cancer. BioMed Central 2020-05-19 /pmc/articles/PMC7236111/ /pubmed/32430034 http://dx.doi.org/10.1186/s12985-020-01340-y Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Sosso, Samuel Martin
Tchouaket, Michel Carlos Tommo
Fokam, Joseph
Simo, Rachel Kamgaing
Torimiro, Judith
Tiga, Aline
Lobe, Elise Elong
Ambada, Georgia
Nange, Achille
Semengue, Ezechiel Ngoufack Jagni
Nka, Alex Durand
Tala, Valère
Chenwi, Collins
Abba, Aissatou
Ka’e, Aude Christelle
Yagai, Bouba
Colizzi, Vittorio
Ndjolo, Alexis
Human immunodeficiency virus is a driven factor of human papilloma virus among women: evidence from a cross-sectional analysis in Yaoundé, Cameroon
title Human immunodeficiency virus is a driven factor of human papilloma virus among women: evidence from a cross-sectional analysis in Yaoundé, Cameroon
title_full Human immunodeficiency virus is a driven factor of human papilloma virus among women: evidence from a cross-sectional analysis in Yaoundé, Cameroon
title_fullStr Human immunodeficiency virus is a driven factor of human papilloma virus among women: evidence from a cross-sectional analysis in Yaoundé, Cameroon
title_full_unstemmed Human immunodeficiency virus is a driven factor of human papilloma virus among women: evidence from a cross-sectional analysis in Yaoundé, Cameroon
title_short Human immunodeficiency virus is a driven factor of human papilloma virus among women: evidence from a cross-sectional analysis in Yaoundé, Cameroon
title_sort human immunodeficiency virus is a driven factor of human papilloma virus among women: evidence from a cross-sectional analysis in yaoundé, cameroon
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7236111/
https://www.ncbi.nlm.nih.gov/pubmed/32430034
http://dx.doi.org/10.1186/s12985-020-01340-y
work_keys_str_mv AT sossosamuelmartin humanimmunodeficiencyvirusisadrivenfactorofhumanpapillomavirusamongwomenevidencefromacrosssectionalanalysisinyaoundecameroon
AT tchouaketmichelcarlostommo humanimmunodeficiencyvirusisadrivenfactorofhumanpapillomavirusamongwomenevidencefromacrosssectionalanalysisinyaoundecameroon
AT fokamjoseph humanimmunodeficiencyvirusisadrivenfactorofhumanpapillomavirusamongwomenevidencefromacrosssectionalanalysisinyaoundecameroon
AT simorachelkamgaing humanimmunodeficiencyvirusisadrivenfactorofhumanpapillomavirusamongwomenevidencefromacrosssectionalanalysisinyaoundecameroon
AT torimirojudith humanimmunodeficiencyvirusisadrivenfactorofhumanpapillomavirusamongwomenevidencefromacrosssectionalanalysisinyaoundecameroon
AT tigaaline humanimmunodeficiencyvirusisadrivenfactorofhumanpapillomavirusamongwomenevidencefromacrosssectionalanalysisinyaoundecameroon
AT lobeeliseelong humanimmunodeficiencyvirusisadrivenfactorofhumanpapillomavirusamongwomenevidencefromacrosssectionalanalysisinyaoundecameroon
AT ambadageorgia humanimmunodeficiencyvirusisadrivenfactorofhumanpapillomavirusamongwomenevidencefromacrosssectionalanalysisinyaoundecameroon
AT nangeachille humanimmunodeficiencyvirusisadrivenfactorofhumanpapillomavirusamongwomenevidencefromacrosssectionalanalysisinyaoundecameroon
AT semengueezechielngoufackjagni humanimmunodeficiencyvirusisadrivenfactorofhumanpapillomavirusamongwomenevidencefromacrosssectionalanalysisinyaoundecameroon
AT nkaalexdurand humanimmunodeficiencyvirusisadrivenfactorofhumanpapillomavirusamongwomenevidencefromacrosssectionalanalysisinyaoundecameroon
AT talavalere humanimmunodeficiencyvirusisadrivenfactorofhumanpapillomavirusamongwomenevidencefromacrosssectionalanalysisinyaoundecameroon
AT chenwicollins humanimmunodeficiencyvirusisadrivenfactorofhumanpapillomavirusamongwomenevidencefromacrosssectionalanalysisinyaoundecameroon
AT abbaaissatou humanimmunodeficiencyvirusisadrivenfactorofhumanpapillomavirusamongwomenevidencefromacrosssectionalanalysisinyaoundecameroon
AT kaeaudechristelle humanimmunodeficiencyvirusisadrivenfactorofhumanpapillomavirusamongwomenevidencefromacrosssectionalanalysisinyaoundecameroon
AT yagaibouba humanimmunodeficiencyvirusisadrivenfactorofhumanpapillomavirusamongwomenevidencefromacrosssectionalanalysisinyaoundecameroon
AT colizzivittorio humanimmunodeficiencyvirusisadrivenfactorofhumanpapillomavirusamongwomenevidencefromacrosssectionalanalysisinyaoundecameroon
AT ndjoloalexis humanimmunodeficiencyvirusisadrivenfactorofhumanpapillomavirusamongwomenevidencefromacrosssectionalanalysisinyaoundecameroon